Managing Tolerability and Setting Patients Up for Success with Cobenfy

Walling discussed how Cobenfy's tolerability profile differs meaningfully from that of atypical antipsychotics, trading cardiometabolic risks and extrapyramidal symptoms for gastrointestinal side effects. Early nausea, which occurred in approximately 49% of the participants, can be managed proactively with antiemetics such as ondansetron (Zofran) and typically resolves over time, he explained. Walling also emphasized the critical importance of patient counseling around Cobenfy's fasting requirements (ie, patients must fast for 1 hour before and 2 hours after dosing) and offered practical strategies such as timing doses mid-morning and taking an antacid just outside the fasting window to reduce acid-related nausea early in treatment.

Throughout the conversation, he provided a comprehensive reflection on the field and the factors that may shape how clinicians approach schizophrenia care moving forward.

Our next episode, "Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy," further explores schizophrenia management, highlighting the broader implications of the data and the practical guidance Walling wants every practicing psychiatric clinician to walk away with.